CCT a strong predictor of glaucoma

Article

Central corneal thickness (CCT) measurements should be included as part of a complete ocular examination, particularly in patients at risk of developing primary open angle glaucoma (POAG), according to a study conducted by the American Academy of Ophthalmology and published in the journal Ophthalmology.

Central corneal thickness (CCT) measurements should be included as part of a complete ocular examination, particularly in patients at risk of developing primary open angle glaucoma (POAG), according to a study conducted by the American Academy of Ophthalmology and published in the journal Ophthalmology.

The investigators conducted a PubMed literature search of all English language articles in 2004 in order to assess whether CCT is a risk factor for the presence, development or progression of glaucomatous optic nerve damage related to POAG. The search yielded 195 articles and, during the in-depth review process, the authors selected an additional 24 studies of interest.

The articles were assigned to one of three categories, depending on the strength of evidence presented in the paper as defined by the panel methodologist. Level I signified a well-designed, properly conducted, randomised clinical trial or similar quality-validated cohort study, with appropriate reference standards. Level II was assigned to well-designed, case-control studies, exploratory cohort studies and other non-randomised clinical studies, lacking consistently applied reference standards. A Level III rating was reserved for poorly designed case-control studies, case series and papers consisting only of expert opinion without supporting evidence. Furthermore, a positive grading was also given to studies in which a statistical association was found between CCT and the risk of having or developing glaucomatous optic nerve damage. All other studies received a negative grading.

The results from Level I and Level II papers showed strong and consistent evidence that CCT is a risk factor for progression from ocular hypertension (OHT) to POAG. Studies, however, that were rated as providing the highest quality of evidence revealed mixed results.

Notwithstanding this, based on the overall results, the authors were able to conclude that measuring CCT is an important component of a complete ocular examination, in particular for patients at risk of developing POAG. They, therefore, urge that CCT measurement be included in the examination of all OHT patients.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.